Gilead Sciences is coming off of a milestone year that saw the start of the much-anticipated launch of the world’s first twice-yearly injectable HIV pre-exposure prophylaxis (PrEP) medicine Ye | ...

Science magazine has chosen twice-yearly lenacapavir PrEP as its 2024 Breakthrough of the Year, recognizing it as a game-changer in the fight to end the global HIV epidemic. Looking ahead, once-yearly ...

Gilead Sciences announced last week it will donate millions of free bottles of Truvada for PrEP to the Centers for Disease Control and Prevention, but many AIDS activists say it is not enough. In a ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV pre-exposure prophylaxis (PrEP) med lenacapavir. The twice-yearly PrEP ...

Tuesday, Gilead Sciences Inc (NASDAQ:GILD) reported fourth-quarter 2024 adjusted EPS of $1.90, beating the consensus of $1.70. Sales increased 6% year over year to $7.57 billion, beating the consensus ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is ...

A Gilead Sciences drug that protects against HIV infection has won a highly anticipated FDA approval, becoming the first medication for HIV prevention available as a twice-yearly injection. The ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief ...

Gilead is edging closer to an approval for its twice-yearly injectable human immunodeficiency virus-1 (HIV-1) capsid ...

Add Yahoo as a preferred source to see more of our stories on Google. Gilead Sciences’ pre-exposure prophylaxis (PrEP) formula of lenacapavir has been approved in the UK as a preventative option for ...